To be honest, I think we need to wait for the SVR12 announcement in mid August before we write the company off, but I agree the options might be worthless unless there is something imminent pending the results.
For me the major issues are the questions around dosing and withdrawals not being sorted and this will take time before being able to progress with any real speed (I know we can test dosing in parallel with future trials, but what you want is zero withdrawals due to negative impacts on patients).
To be honest, I think we need to wait for the SVR12 announcement...
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
